Leerink raised the company’s target price about Vertex Pharmaceuticals (VRTX) to $525 from $456 and maintains an outperform rating on the stock. The company cites an increase in its terminal growth assumption from 1% to 2%. Leerink is bullish on the company’s revenue and outlook, which he expects to drive share price performance. The company would caution that it projects higher growth in investment spending than consensus models.
First published in The Fly – the ultimate source for breaking, real-time market-moving financial news. Try now >>
Check out the best stocks recommended by analysts >>
Read more about VRTX:






